ArticleACS omega2026
5'-NucA-SMCC-DM1 and 5'-NucA-SPDMV-DM1 are Potent Aptamer-Drug Conjugates against Pancreatic Cancer.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most lethal cancers, characterized by low survival rates due to a complex tumor microenvironment, late-stage diagnosis and, notably, the limited effectiveness of current treatments. First-line therapies, such as gemcitabine and nab-paclitaxel, often lead to unexpected side effects. Mertansine, which is a more potent cytotoxic agent, faces similar challenges. In response, we designed and synthesized a highly water-soluble conjugate of an antinucleolin aptamer (NucA) and mertansine (NucA-DM1) to enhance the delivery of DM1 specifically to pancreatic tumor cells. Our
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.